This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $126.62, marking a +0.56% move from the previous day.
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.
Company News for Jul 7, 2023
by Zacks Equity Research
Companies in The News Are: JBLU, AAL, F, MRNA, GENI.
Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine
by Zacks Equity Research
Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
by Zacks Equity Research
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $123.54, moving +1.49% from the previous trading session.
Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab
by Zacks Equity Research
Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $123 in the latest trading session, marking a +1.93% move from the prior day.
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $120.48, marking a -0.49% move from the previous day.
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
by Sanghamitra Saha
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $128.73, moving -0.96% from the previous trading session.
FDA Panel Endorses Updating COVID Jab to Target XBB Strain
by Zacks Equity Research
An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.
Company News for Jun 16, 2023
by Zacks Equity Research
Companies in The News Are: JD, KR, MRNA, JBL
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $126.05 in the latest trading session, marking a -1.51% move from the prior day.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $124.94, marking a -0.53% move from the previous day.
Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading
by Zacks Equity Research
Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
by Zacks Equity Research
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH